Company Summary:
Quotient Therapeutics, Inc. is a privately held, early-stage company developing a novel genomics platform and therapeutics for diseases with a large unmet need.
Quotient Therapeutics, Inc. was founded by Flagship Pioneering, an innovation enterprise that conceives, creates, resources, and grows first-in-category life sciences companies. Flagship Pioneering has created over 100 groundbreaking companies over the past twenty years, all of which are pioneering novel and proprietary biological, industrial, and engineering approaches to solve major needs in human health and sustainability. These companies include Moderna (MRNA), Seres Therapeutics (NASDAQ: MCRB), Sana Biotechnology (SANA), Axcella Health (AXLA), Indigo Agriculture, Generate Biomedicines, and Tessera Therapeutics.
Position Summary:
We are seeking a Head of Target Discovery that reports to the Chief Science Officer and leads a team of scientists to drive the end-to-end target discovery process, including indication prioritization, feasibility assessment, study design, study execution and study interpretation. We are looking for someone who can think creatively, is enthusiastic about exploring many different diseases, and has experience applying genomics to the study of human disease. The ideal candidate operates with strong scientific rigor, pays attention to detail, and has a deep-rooted desire to innovate. Being collaborative is key – in this function, there will be many interactions with other leaders at Quotient, such as in data science, assay development, and target biology. This role is based in the vicinity of Cambridge UK and will be primarily based on site. All applicants will require permission to work in the UK.
Key Responsibilities:
- Lead target discovery science at Quotient, including study design, execution and interpretation
- Lead a team of genomics scientists, who themselves lead or contribute to the end-to-end target discovery process, leveraging cross-functional project teams
- Work directly with the CSO to drive towards major corporate goals and own strategic initiatives
- Take a leading role in indication selection, establishing a deep understanding of diverse therapeutic areas and disease indications
- Set a high bar for target discovery science, aiming for rigorous quality at every level of scientific output
- Collaborate with other leaders at Quotient, constantly seeking ways to run efficient and high-quality studies
- Interact with external stakeholders to represent target discovery science, working alongside business development colleagues
Qualifications:
- Ph.D. in biology or related discipline with 10+ years of relevant post-Ph.D. experience with an excellent track record of discovering therapeutic targets in a variety of diseases
- Background in human genetics, evolutionary biology, or cancer genomics
- Breadth of therapeutic area expertise in the context of therapeutic target and drug discovery
- Experience applying genomics methods to the study of human disease
- Team leadership experience, ideally in the setting of a matrixed project organization
- Strong written and verbal communication, capable of communicating complex datasets to internal and external stakeholders
- Prior experience working with or leading collaborations with external academic, biotechnology, and contract research organizations
About Flagship
Flagship Pioneering is a bioplatform innovation company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $90 billion in aggregate value. Many of the companies Flagship has founded have addressed humanity’s most urgent challenges: vaccinating billions of people against COVID-19, curing intractable diseases, improving human health, preempting illness, and feeding the world by improving the resiliency and sustainability of agriculture. Flagship has been recognized twice on FORTUNE’s “Change the World” list, an annual ranking of companies that have made a positive social and environmental impact through activities that are part of their core business strategies, and has been twice named to Fast Company’s annual list of the World’s Most Innovative Companies. Learn more about Flagship at www.flagshippioneering.com.
Flagship Pioneering and our ecosystem companies are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.
At Flagship, we recognize there is no perfect candidate. If you have some of the experience listed above but not all, please apply anyway. Experience comes in many forms, skills are transferable, and passion goes a long way. We are dedicated to building diverse and inclusive teams and look forward to learning more about your unique background.
Recruitment & Staffing Agencies: Flagship Pioneering and its affiliated Flagship Lab companies (collectively, “FSP”) do not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to FSP or its employees is strictly prohibited unless contacted directly by Flagship Pioneering’s internal Talent Acquisition team. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of FSP, and FSP will not owe any referral or other fees with respect thereto.
Top Skills
What We Do
Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability.
Since its launch in 2000, the firm has applied a unique, hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $30 billion in aggregate value. To date, Flagship is backed by >$3 billion of aggregate capital commitments, of which over $1.5 billion has been deployed toward the founding and growth of its pioneering companies alongside >$10 billion of follow-on investments from other institutions.
The current Flagship ecosystem includes Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Moderna Therapeutics (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Seres Therapeutics (NASDAQ: MCRB), and Syros Pharmaceuticals (NASDAQ: SYRS).
.png)
